These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24746301)

  • 1. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy.
    Gutiérrez-González E; Batalla A; de la Mano D
    Dermatol Online J; 2014 Apr; 20(4):22338. PubMed ID: 24746301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple lentigines arising in resolving psoriatic plaques after treatment with etanercept.
    Costa LA; Belinchón I; Betlloch I; Pérez-Crespo M; Mataix J
    Dermatol Online J; 2008 Jan; 14(1):11. PubMed ID: 18319028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple lentigines confined to resolving psoriatic plaques in a patient treated with adalimumab.
    Santos-Juanes J; Coto P; Mallo S; Galache C; Sánchez del Río J; Torre JC
    Dermatology; 2008; 216(3):279. PubMed ID: 18216489
    [No Abstract]   [Full Text] [Related]  

  • 4. Lentigines in previous psoriatic plaques in a patient treated with infliximab.
    Bardazzi F; Magnano M; Antonucci VA; Balestri R; Sgubbi P; Patrizi A
    Eur J Dermatol; 2012; 22(5):698-9. PubMed ID: 22940696
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB; Ibler KS
    J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple lentigines confined to a resolving psoriatic plaque.
    Martí N; Molina I; López V; Terradez L; Jordá E
    Dermatol Online J; 2009 Oct; 15(10):15. PubMed ID: 19951633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lentigines in resolving psoriatic plaques: rarely reported sequelae in pediatric cases.
    LaRosa CL; Foulke GT; Feigenbaum DF; Cordoro KM; Zaenglein AL
    Pediatr Dermatol; 2015; 32(3):e114-7. PubMed ID: 25727728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.
    Gniadecki R; Bang B; Sand C
    Br J Dermatol; 2016 May; 174(5):1145-6. PubMed ID: 26522308
    [No Abstract]   [Full Text] [Related]  

  • 10. The efficacy of ustekinumab in psoriasis.
    Famenini S; Wu JJ
    J Drugs Dermatol; 2013 Mar; 12(3):317-20. PubMed ID: 23545915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythrodermic psoriasis: current and future role of biologicals.
    Stinco G; Errichetti E
    BioDrugs; 2015 Apr; 29(2):91-101. PubMed ID: 25752640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
    Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
    J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma.
    Wang DM; Fernandez AP; Calabrese CM; Calabrese LH
    Clin Exp Dermatol; 2019 Jan; 44(1):113-115. PubMed ID: 29797733
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a side effect of biological therapy?
    Conti A; Esposito I; Lasagni C; Miglietta R; Padalino C; Fabiano A; Pellacani G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S35-7. PubMed ID: 25381972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.